|
|
|
|
| LEADER |
04922nmm a2200313 u 4500 |
| 001 |
EB000668786 |
| 003 |
EBX01000000000000000521868 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642658068
|
| 100 |
1 |
|
|a Sartorelli, Alan C.
|
| 245 |
0 |
0 |
|a Antineoplastic and Immunosuppressive Agents
|h Elektronische Ressource
|b Part II
|c by Alan C. Sartorelli, David G. Johns
|
| 250 |
|
|
|a 1st ed. 1975
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1975, 1975
|
| 300 |
|
|
|b online resource
|
| 505 |
0 |
|
|a II Table of Contents -- Section C: Alkylating Agents -- 30 Chemistry of Alkylation -- 31 Molecular Biology of Alkylation: An Overview -- 32 Mechanism of Action of 2-Chloroethylamine Derivatives, Sulfur Mustards, Epoxides, and Aziridines -- 33 Mechanism of Action of Methanesulfonates -- 34 Mechanism of Action of Mitomycins -- 35 Mechanism of Action of Nitrosoureas -- Section D: Hormones -- 36 Mechanism of Action of Glucocorticoids -- 37 Mechanisms of Action of Estrogens -- 38 Mechanism of Action of Androgens -- 39 Mechanism of Action of Progesterone -- 40 Pharmacology and Clinical Utility of Hormones in Hormone Belated Neoplasms -- Section E: Antimetabolites -- 41 Fluorinated Pyrimidines and Their Nucleosides -- 42 Arabinosylcytosine -- 43 Clinical Pharmacology of Arabinosylcytosine -- 44 Halogenated Pyrimidine Deoxyribonucleosides -- 45 Azapyrimidine Nucleosides -- 46 Showdomycin, 5-Hydroxyuridine, and 5-Aminouridine -- 47 6-Thiopurines -- 48 Azathioprine --
|
| 505 |
0 |
|
|a 72 Clinical and Pharmacologic Effects of Hydroxyurea -- 73 ?-(N)-Heterocyclic Carboxaldehyde Thiosemicarbazones -- 74 1-(o-Chlorophenyl)-1-(p-Chlorophenyl)-2,2-Dichloroethane (o,p?-DDD), an Adrenocorticolytic Agent -- 75 The Phthalanllides -- 76 Platinum Compounds -- 77 Metal Chelates of 3-Ethoxy-2-Oxobutyraldehyde bis (Thiosemicarbazone), H2KTS -- 78 Phleomycin and Bleomycin -- 79 Pharmacology of Newer Antineoplastic Agents -- Addendum to Cytotoxic Analogs of Pyridine Nucleotide Coenzymes -- Author Index
|
| 505 |
0 |
|
|a 49 Purine Arabinosides, Xylosides, and Lyxosides -- 50 Antibiotics Resembling Adenosine: Tubereidin, Toyocamycin, Sangivamycin, Formycin, Psicofuranine, and Decoyinine -- 51 8-Azaguanine -- 52 Folate Antagonists -- 53 Glutamine Antagonists -- 54 Cytotoxic Amino Acid Analogs -- 55 Cytotoxic Analogs of Pyridine Nucleotide Coenzymes -- 56 Triazenoimidazoie Derivatives -- Section F: Additional Cytotoxic Agents -- 57 Cytotoxic Inhibitors of Protein Synthesis -- 58 Selective Interruption of RNA Metabolism by Chemotherapeutic Agents -- 59 Actinomycin -- 60 Dannomycin (Daunorubiein) and Adriamycin -- 61 Chromomycin, Olivomycin, and Mithramycin -- 62 Nogalamyein -- 63 Streptonigrin -- 64 Anthramycin -- 65 Camptothecin -- 66 3?-Deoxyadenosine and Other Polynucleotide Chain Terminators -- 67 Yinea Alkaloids and Colchicine -- 68 L-Asparaginase: Basic Aspects -- 69L-Asparaginase: Current Status of Clinieal Evaluation -- 70 Procarbazine -- 71 Bis-Guanylhydrazones --
|
| 653 |
|
|
|a Pharmacy
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Johns, David G.
|e [author]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-65806-8
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-65806-8?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615.1
|
| 520 |
|
|
|a Over the past two decades a number of attempts have been made, with varying degrees of success, to collect in a single treatise available information on the basic and applied pharmacology and biochemical mechanism of action of antineoplastic and immunosuppressive agents. The logarithmic growth of knowledge in this field has made it progressively more difficult to do justice to all aspects of this topic, and it is possible that the present handbook, more than four years in preparation, may be the last attempt to survey in a single volume the entire field of drugs employed in cancer chemotherapy and immunosuppression. Even in the present instance, it has proved necessary for practical reasons to publish the material in two parts, although the plan of the work constitutes, at least in the editors' view, a single integrated treatment of this research area. A number of factors have contributed to the continuous expansion of research in the areas of cancer chemotherapy and immunosuppression. Active compounds have been emerging at ever-increasing rates from experimental tumor screening systems maintained by a variety of private and governmental laboratories through out the world. At the molecular level, knowledge of the modes of action of established agents has continued to expand, and has permitted rational drug design to play a significantly greater role in a process which, in its early years, depended almost completely upon empirical and fortuitous observations
|